Clearside Biomedical

Brion Raymond

Show Description +

Brion Raymond, Chief Commercial Officer, Clearside Biomedical, provides an update on the company's lead product candidate, suprachoroidal CLS-TA, which is in clinical development for several indications including uveitis, retinal vein occlusion, and diabetic macular edema (DME).

Posted: 7/23/2018

Keywords:

Diabetic macular edema, DME

•

Retinal Vein Occlusion, RVO

•

suprachoroidal CLS-TA

Up Next

Name: Clearside Biomedical
Uploaded: 2018-07-23T15:17:00+00:00
Description: Brion Raymond, Chief Commercial Officer, Clearside Biomedical, provides an update on the company's lead product candidate, suprachoroidal CLS-TA, which is in clinical development for several indications including uveitis, retinal vein occlusion, and diabetic macular edema (DME).